Electrocardiographic parameters of left ventricular hypertrophy and prediction of mortality in hemodialysis patients.
Cardiovascular mortality
Hemodialysis
Left ventricular hypertrophy
Peguero-Lo presti
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
01
03
2021
accepted:
09
05
2021
pubmed:
21
5
2021
medline:
24
3
2022
entrez:
20
5
2021
Statut:
ppublish
Résumé
In hemodialysis patients, left ventricular hypertrophy (LVH) contributes to high cardiovascular mortality. We examined cardiovascular mortality prediction by the recently proposed Peguero-Lo Presti voltage since it identifies more patients with electrocardiographic (ECG) LVH than Cornell or Sokolow-Lyon voltages. A total of 308 patients on hemodialysis underwent 24 h ECG recordings. LVH parameters were measured before and after dialysis. The primary endpoint of cardiovascular mortality was recorded during a median 3-year follow up. Risk prediction was assessed by Cox regression, both unadjusted and adjusted for the Charlson Comorbidity Index and the Cardiovascular Mortality Risk Score. The Peguero-Lo Presti voltage identified with 21% the most patients with positive LVH criteria. All voltages significantly increased during dialysis. Factors such as ultrafiltration rate, Kt/V, body mass index, sex, and phosphate were the most relevant for these changes. During follow-up, 26 cardiovascular deaths occurred. Post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages were independently associated with cardiovascular mortality in unadjusted and adjusted analysis. The Sokolow-Lyon voltage was not significantly associated with mortality. An optimal cut-off for the prediction of cardiovascular mortality was estimated at 1.38 mV for the Peguero-Lo Presti. The post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages allowed independent risk prediction of cardiovascular mortality in hemodialysis patients. Measuring the ECG LVH parameters after dialysis might allow a standardized interpretation as dialysis-specific factors influence the voltages.
Sections du résumé
BACKGROUND
BACKGROUND
In hemodialysis patients, left ventricular hypertrophy (LVH) contributes to high cardiovascular mortality. We examined cardiovascular mortality prediction by the recently proposed Peguero-Lo Presti voltage since it identifies more patients with electrocardiographic (ECG) LVH than Cornell or Sokolow-Lyon voltages.
METHODS
METHODS
A total of 308 patients on hemodialysis underwent 24 h ECG recordings. LVH parameters were measured before and after dialysis. The primary endpoint of cardiovascular mortality was recorded during a median 3-year follow up. Risk prediction was assessed by Cox regression, both unadjusted and adjusted for the Charlson Comorbidity Index and the Cardiovascular Mortality Risk Score.
RESULTS
RESULTS
The Peguero-Lo Presti voltage identified with 21% the most patients with positive LVH criteria. All voltages significantly increased during dialysis. Factors such as ultrafiltration rate, Kt/V, body mass index, sex, and phosphate were the most relevant for these changes. During follow-up, 26 cardiovascular deaths occurred. Post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages were independently associated with cardiovascular mortality in unadjusted and adjusted analysis. The Sokolow-Lyon voltage was not significantly associated with mortality. An optimal cut-off for the prediction of cardiovascular mortality was estimated at 1.38 mV for the Peguero-Lo Presti.
CONCLUSIONS
CONCLUSIONS
The post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages allowed independent risk prediction of cardiovascular mortality in hemodialysis patients. Measuring the ECG LVH parameters after dialysis might allow a standardized interpretation as dialysis-specific factors influence the voltages.
Identifiants
pubmed: 34014512
doi: 10.1007/s40620-021-01068-0
pii: 10.1007/s40620-021-01068-0
pmc: PMC8803820
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-244Informations de copyright
© 2021. The Author(s).
Références
JAMA. 2007 Sep 19;298(11):1291-9
pubmed: 17878421
Am J Kidney Dis. 2016 Nov;68(5S1):S5-S14
pubmed: 27772643
J Cardiovasc Magn Reson. 2018 Dec 17;20(1):83
pubmed: 30554567
Curr Opin Nephrol Hypertens. 2014 Nov;23(6):578-85
pubmed: 25295959
Nephrol Dial Transplant. 2013 Sep;28(9):2228-36
pubmed: 23625971
Ann Noninvasive Electrocardiol. 2013 Mar;18(2):188-98
pubmed: 23530490
J Electrocardiol. 2016 Nov - Dec;49(6):855-859
pubmed: 27613393
Semin Dial. 2008 Jul-Aug;21(4):308-18
pubmed: 18627569
J Electrocardiol. 2008 Jan-Feb;41(1):60.e1-7
pubmed: 17027839
Circulation. 1990 Mar;81(3):815-20
pubmed: 2137733
BMC Nephrol. 2016 Oct 26;17(1):161
pubmed: 27784272
J Am Coll Cardiol. 2017 Apr 4;69(13):1694-1703
pubmed: 28359515
Am J Kidney Dis. 2005 Aug;46(2):320-7
pubmed: 16112052
Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9
pubmed: 9820470
J Am Heart Assoc. 2017 Jan 22;6(1):
pubmed: 28111363
Circulation. 2001 May 15;103(19):2346-51
pubmed: 11352882
Kidney Int. 2010 Jan;77(2):141-51
pubmed: 19907414
J Am Coll Cardiol. 2009 Mar 17;53(11):992-1002
pubmed: 19281932
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Kidney Int. 1995 Jan;47(1):186-92
pubmed: 7731145
Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S79-91
pubmed: 19996010
J Hypertens. 2017 Jan;35(1):162-169
pubmed: 27662187
Am J Kidney Dis. 2016 Oct;68(4):554-563
pubmed: 27138469
Heart Rhythm. 2014 Jun;11(6):1040-6
pubmed: 24657425
Circulation. 1987 Mar;75(3):565-72
pubmed: 2949887
Kidney Int. 2004 Apr;65(4):1492-8
pubmed: 15086493
J Am Soc Nephrol. 2001 Dec;12(12):2759-2767
pubmed: 11729246
Curr Cardiol Rev. 2014 Aug;10(3):257-61
pubmed: 24827796
Am J Med. 2018 Jan;131(1):101.e1-101.e8
pubmed: 28803927
Kidney Int. 2006 Jun;69(12):2268-73
pubmed: 16672908
Nephrol Dial Transplant. 1990;5(1):39-44
pubmed: 2109283
Nephrol Dial Transplant. 2020 Nov 1;35(11):2020
pubmed: 31436826
Nephrol Dial Transplant. 1998 Jun;13(6):1489-93
pubmed: 9641180
Nat Rev Nephrol. 2011 Nov 01;8(3):141-50
pubmed: 22045239
Am J Med Sci. 2013 Jan;345(1):1-9
pubmed: 23018492
Int J Cardiol. 2016 Aug 1;216:68-77
pubmed: 27140339
Kidney Int. 2018 Apr;93(4):941-951
pubmed: 29395340
N Engl J Med. 2010 Dec 9;363(24):2287-300
pubmed: 21091062
Clin J Am Soc Nephrol. 2008 Mar;3(2):505-21
pubmed: 18184879
J Am Coll Cardiol. 2016 Mar 15;67(10):1173-1182
pubmed: 26965538
Am Heart J. 1949 Feb;37(2):161-86
pubmed: 18107386
Int J Cardiol. 2019 Feb 1;276:125-129
pubmed: 30293667
Clin J Am Soc Nephrol. 2011 Mar;6(3):528-36
pubmed: 21088286
Kidney Int. 1999 Dec;56(6):2248-53
pubmed: 10594802